Workflow
NRX Pharmaceuticals(NRXP)
icon
Search documents
NRX Pharmaceuticals(NRXP) - 2021 Q3 - Earnings Call Transcript
2021-11-16 19:18
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2021 Earnings Conference Call November 16, 2021 8:30 AM ET Company Participants Eric Goldstein - Managing Director, LifeSci Advisors Jonathan Javitt - Chairman and Chief Executive Officer Randy Guggenheimer - Chief Business Officer Operator Good morning, everyone and welcome to the NRx Pharmaceuticals??? Third Quarter Results and Conference Call. Currently, participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being ...
NRX Pharmaceuticals(NRXP) - 2021 Q3 - Quarterly Report
2021-11-15 21:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39412 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other juri ...
NRX Pharmaceuticals(NRXP) - 2021 Q2 - Earnings Call Transcript
2021-08-17 20:39
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2021 Results Conference Call August 17, 2021 8:30 AM ET Company Participants Eric Goldstein - Managing Director, LifeSci Advisors Jonathan Javitt - Chairman and Chief Executive Officer Randy Guggenheimer - Chief Business Officer Robert Besthof - Chief Commercial Officer Operator Greetings, and welcome to the NRx Pharma Second Quarter 2021 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal pr ...
NRX Pharmaceuticals(NRXP) - 2021 Q2 - Quarterly Report
2021-08-16 21:21
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39412 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdict ...
NRX Pharmaceuticals(NRXP) - 2021 Q1 - Quarterly Report
2021-05-20 23:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38302 BIG ROCK PARTNERS ACQUISITION CORP. (Exact name of registrant as specified in its charter) ( ...
NRX Pharmaceuticals(NRXP) - 2020 Q4 - Annual Report
2021-04-01 21:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 BIG ROCK PARTNERS ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 82-2844431 (State or othe ...
NRX Pharmaceuticals(NRXP) - 2020 Q3 - Quarterly Report
2020-11-16 21:55
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38302 BIG ROCK PARTNERS ACQUISITION CORP. (Exact name of registrant as specified in its charter) | Delaware | 82 ...
NRX Pharmaceuticals(NRXP) - 2020 Q2 - Quarterly Report
2020-08-14 20:49
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q BIG ROCK PARTNERS ACQUISITION CORP. (Exact name of registrant as specified in its charter) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Delaware | 82-2844431 | | --- | --- | | (State or other jurisdiction of incorporation | (I.R.S. Employer Identification Number) | | or organization) | | | 2645 N. Federal Highway, Suite 230 | | | Delray Beach, FL | 33483 | For the transition peri ...
NRX Pharmaceuticals(NRXP) - 2020 Q1 - Quarterly Report
2020-05-15 20:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38302 BIG ROCK PARTNERS ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 82-2844431 ...
NRX Pharmaceuticals(NRXP) - 2019 Q4 - Annual Report
2020-03-30 21:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 BIG ROCK PARTNERS ACQUISITION CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...